---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-012417"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T21:27:24.966230+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DMK Pharma appoints new CFO and General Counsel amid Nasdaq delisting risk

## Summary
- Appointed Seth Cohen as CFO (base salary $400k) and John Dorbin as General Counsel (base salary $230k).
- Nasdaq issued superseding notice: Company not eligible for 180-day grace period on bid price rule due to prior monitor status.
- Hearing scheduled to address bid price and MVLS non-compliance; delisting possible if extension not granted.
- Cohen receives inducement option for 151,416 shares at $0.6016; Dorbin recommended for 70,000 shares.

## SEC filing metadata
- accession: 0001387131-23-012417
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/0001387131-23-012417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/dmk-8k_101623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-012417
- JSON: https://secwatch.observer/filing/0001387131-23-012417.json
- Plain text: https://secwatch.observer/filing/0001387131-23-012417.txt

## Key facts
- Listing & Compliance Notices
  DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: October 11, 2023, the Company received notice from the Staff that, due to the Company’s failure to regain compliance with the minimum $35 million market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) during the 180-day grace period previously granted to the Company that expired on October 9, 2023, the Company’s common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). In response, the Company timely requested a hearing before the Panel, which request stayed a
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/0001387131-23-012417-index.htm
- Listing & Compliance Notices
  DMK PHARMACEUTICALS Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: October 18, 2023, the Company received a superseding notice from the Staff (the “Subsequent Notice”), indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company’s non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan t
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/0001387131-23-012417-index.htm
- Executive change
  David J. Marguglio departed as Chief Financial Officer (interim) at DMK PHARMACEUTICALS Corp.
  - Action: replaced
  - Role: Chief Financial Officer (interim)
  source text: On October 16, 2023, DMK Pharmaceuticals Corporation (the “Company”) appointed Seth A. Cohen as the Company’s Chief Financial Officer, replacing David J. Marguglio, who had served on an interim basis as Chief Financial Officer since July 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/0001387131-23-012417-index.htm
- Executive change
  Seth A. Cohen was appointed as Chief Financial Officer at DMK PHARMACEUTICALS Corp.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 16, 2023, DMK Pharmaceuticals Corporation (the “Company”) appointed Seth A. Cohen as the Company’s Chief Financial Officer, replacing David J. Marguglio, who had served on an interim basis as Chief Financial Officer since July 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/0001387131-23-012417-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.